

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

MOCHIZUKI *et al.*

Appln. No.: 09/834,008

Filed: April 12, 2001

For: Bone-Pathobolism Treating Agent

Group Art Unit: 1653

Examiner: Chih Min Kam

Confirmation No.: 4949

Atty. Docket: 16991.008

Supplemental Information Disclosure Statement

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

The attention of the Examiner is invited to the documents listed on the attached Form PTO-1449. Copies of the listed documents are submitted herewith.

It is respectfully requested that the information above be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.


Certification and/or Fee

Because this Supplemental Information Disclosure Statement is being submitted after issuance of the first action on the merits of the above-captioned application, a fee of \$180.00 is due pursuant to 37 C.F.R. § 1.17(p). Authorization to charge the official fees for this filing is given in the accompanying transmittal letter.

04/08/2004 KBETEMA1 00000046 502387 09834008

01 FC:1806 180.00 DA

Respectfully submitted,



David R. Marsh (Reg. Attorney No. 41,408)
Dawn Gardner Krosnick (Reg. Attorney No. 44,118)

Date: April 7, 2004

ARNOLD & PORTER LLP
555 Twelfth Street, N.W.
Washington, D.C. 20004-1206
(202) 942-5000 telephone
(202) 942-5999 facsimile



**SUPPLEMENTAL
FORM PTO-1449
INFORMATION DISCLOSURE STATEMENT**

ATTY. DOCKET NO.	APPLICATION NO.
16991.008	09/834,008
APPLICANTS	
Mochizuki <i>et al.</i>	
FILING DATE	GROUP
April 12, 2001	1653

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA1	6,015,938	1/18/2000	Boyle <i>et al.</i>			
	AB1	6,284,485 B1	9/4/2001	Boyle <i>et al.</i>			
	AC1	6,284,728 B1	9/4/2001	Boyle <i>et al.</i>			
	AD1	6,284,740 B1	9/4/2001	Boyle <i>et al.</i>			
	AE1	6,288,032 B1	9/11/2001	Boyle <i>et al.</i>			
	AF1	6,369,027 B1	4/9/2002	Boyle <i>et al.</i>			
	AG1	6,613,544 B1	9/2/2003	Boyle <i>et al.</i>			
	AH1	6,693,175 B2	2/17/2004	Yano <i>et al.</i>			
	AI1	2002/0051969 A1	5/2/2002	Goto <i>et al.</i>			
	AJ1	2003/0153048 A1	8/14/2003	Goto <i>et al.</i>			
	AK1	2003/0181418 A1	9/25/2003	Kumakura <i>et al.</i>			
	AL1	2003/0207827 A1	11/6/2003	Boyle <i>et al.</i>			
	AM1	2003/0216297 A1	11/20/2003	Kumakura <i>et al.</i>			


FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AN1	0 874 045 A1	10/28/1998	EPO			Yes No
	AO1	0 911 342 A1	4/28/1999	EPO			Yes No
	AP1	0 974 671 A1	1/26/2000	EPO			Yes No
	AQ1	96/26217	8/29/1996	PCT			X Yes No
	AR1	97/23614	7/3/1997	PCT			Yes No
	AS1	99/15691	4/1/1999	PCT			Abstract Yes only No
	AT1	03/074084	9/12/2003	PCT			Yes No

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



SUPPLEMENTAL
FORM PTO-1449
INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.	APPLICATION NO.
16991.008	09/834,008
APPLICANTS	
Mochizuki <i>et al.</i>	
FILING DATE	GROUP
April 12, 2001	1653

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AA2	J. Body, "Current and Future Directions in Medical Therapy: <i>Hypercalcemia</i> ", <i>CANCER Supplement</i> , 88 (12):3054-3058 (2000)
AB2	E. Romas <i>et al.</i> , "Involvement of Receptor Activator of NF κ B Ligand and Tumor Necrosis Factor- α in Bone Destruction in Rheumatoid Arthritis", <i>Bone</i> , 30 (2):340-346 (2002)
AC2	B. Fautrel <i>et al.</i> , "Cost of Illness Studies in Rheumatic Diseases", <i>Current Opinion in Rheumatology</i> , 14:121-126 (2002)
AD2	M. Iqbal <i>et al.</i> , "Osteoporosis: A Review", <i>Missouri Medicine</i> , 99 (1):19-24 (2002)
AE2	J. White <i>et al.</i> , "Postmenopausal Hormone Replacement: Historical Perspectives and Current Concerns", <i>Clinical Excellence for Nurse Practitioners</i> , 4 (5):277-285 (2000)
AF2	J. Green <i>et al.</i> , "Renal Tolerability Profile of Novel, Potent Bisphosphonates in Two Short-Term Rat Models", <i>Pharmacology and Toxicology</i> , 80:225-230 (1997)
AG2	S. Porcel <i>et al.</i> , "Anaphylaxis to calcitonin", <i>Allergologia et Immunopathologia</i> , 28 (4), 243-245 (2000)
AH2	W. S. Simonet <i>et al.</i> , "Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density" <i>Cell</i> , 89:309-319 (1997)
AI2	
AJ2	
AK2	
AL2	
AM2	

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.